{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T20:42:53Z","timestamp":1784234573169,"version":"3.55.0"},"reference-count":41,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Ocular Pharmacology and Therapeutics"],"published-print":{"date-parts":[[2024,8,1]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>\n                      To assess the impact of switching to, or adding, an intravitreal dexamethasone implant (Dex; Ozurdex\n                      <jats:sup>\u00ae<\/jats:sup>\n                      ) in anti-vascular endothelial growth factor (VEGF) therapy on disease stability and treatment intervals in eyes with neovascular age-related macular degeneration (nAMD) and persistent disease activity and high treatment demand.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This retrospective noncomparative multicenter longitudinal case series included pseudophakic eyes with nAMD and persistent retinal fluid despite regular anti-VEGF therapy (ranibizumab or aflibercept) that received at least 1 intravitreal Dex implant. Visual acuity, central retinal thickness (CRT), and intraocular pressure were recorded before, and after, the addition of Dex to anti-VEGF therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Sixteen eyes of 16 patients met the inclusion criteria of persistent fluid despite anti-VEGF therapy, under treatment intervals of \u22647 weeks in 14 instances. Patients were 80.9\u2009\u00b1\u20097.4 years old and had received 25.5\u2009\u00b1\u200917.4 anti-VEGF injections before Dex over a period of 36.4\u2009\u00b1\u200921.9 months before switching. The treatment interval increased from 5.5\u2009\u00b1\u20093.2 weeks between the last anti-VEGF and first Dex injection to 11.7\u2009\u00b1\u20097.3 weeks thereafter (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u20090.022). CRT remained stable (385.3\u2009\u00b1\u2009152.1, 383.9\u2009\u00b1\u2009129.7, and 458.3\u2009\u00b1\u2009155.2\u2009\u03bcm before switching as well as 12 and 24 months after switching\n                      <jats:italic toggle=\"yes\">; P<\/jats:italic>\n                      \u2009=\u20090.78 and\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u20090.36, respectively). An insignificant mean short-term early increase in visual acuity was not sustained over time.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>The addition of Dex resulted in a relevant and sustained increase in treatment intervals, whereas CRT and visual acuity remained stable in these difficult-to-treat eyes. It may be discussed whether inflammation or other steroid-responsive factors play a significant role in cases of nAMD with nonsatisfactory responses to anti-VEGF.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/jop.2023.0105","type":"journal-article","created":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T12:33:20Z","timestamp":1703075600000},"page":"361-369","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":4,"title":["Intravitreal Dexamethasone as a Rescue for Anti-Vascular Endothelial Growth Factor Therapy in Neovascular Age-Related Macular Degeneration with Persistent Disease Activity and High Treatment Demand"],"prefix":"10.1177","volume":"40","author":[{"given":"Marlena","family":"Pietzuch","sequence":"first","affiliation":[{"name":"Swiss Eye Institute and Clinic for Vitreoretinal Diseases, Berner Augenklinik, Bern, Switzerland."},{"name":"Department of Ophthalmology, Bern University Hospital, Bern, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irmela","family":"Mantel","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of Lausanne, Jules Gonin Eye Hospital, Lausanne, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aude","family":"Ambresin","sequence":"additional","affiliation":[{"name":"Swiss Visio Clinic Montchoisi, Lausanne, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Tappeiner","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Pallas Kliniken, Olten, Switzerland."},{"name":"Department of Ophthalmology, University Hospital Essen, University Duisburg-Essen, Essen, Germany."},{"name":"Medical Faculty, University of Bern, Bern, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Nagyova","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Pallas Kliniken, Olten, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Donati","sequence":"additional","affiliation":[{"name":"Centre Ophtalmologique de la Colline, Hirshlanden Clinics and Clinique d'Ophtalmologie, H\u00f4pitaux Universitaires de Gen\u00e8ve, Geneva, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel B.","family":"Pfister","sequence":"additional","affiliation":[{"name":"Swiss Eye Institute and Clinic for Vitreoretinal Diseases, Berner Augenklinik, Bern, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christin","family":"Schild","sequence":"additional","affiliation":[{"name":"Swiss Eye Institute and Clinic for Vitreoretinal Diseases, Berner Augenklinik, Bern, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justus G.","family":"Garweg","sequence":"additional","affiliation":[{"name":"Swiss Eye Institute and Clinic for Vitreoretinal Diseases, Berner Augenklinik, Bern, Switzerland."},{"name":"Department of Ophthalmology, Bern University Hospital, Bern, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,8,19]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(13)70145-1"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(17)30393-5"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.4103\/1673-5374.332147"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1080\/14728222.2022.2030706"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2013.818"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.64.5.28"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000003798"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.594087"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2023.02.008"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-023-02780-0"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-018-04232-8"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21218242"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11071834"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2013-304736"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-020-05048-1"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-011-1734-5"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.4274\/tjo.galenos.2020.38488"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2023.02.021"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200826010-00006"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10143106"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.3928\/23258160-20180221-03"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1350-9462(00)00025-2"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-020-01354-4"},{"issue":"1","key":"e_1_3_4_25_2","first-page":"Cd005022","article-title":"Surgical implantation of steroids with antiangiogenic characteristics for treating neovascular age-related macular degeneration","volume":"1","author":"Geltzer A","year":"2013","unstructured":"Geltzer A, , Turalba A, , Vedula SS. Surgical implantation of steroids with antiangiogenic characteristics for treating neovascular age-related macular degeneration. Cochrane Database Syst Rev, 2013; 1(1):Cd005022.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006982-200003000-00004"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.17-22259"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.4103\/tjo.tjo_68_19"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S224456"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1177\/2474126416683299"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2014-306002"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e3181d87e04"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcjo.2016.04.020"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11101024"},{"key":"e_1_3_4_35_2","doi-asserted-by":"crossref","first-page":"5612342","DOI":"10.1155\/2018\/5612342","article-title":"Intravitreal dexamethasone in patients with wet age-related macular degeneration resistant to anti-VEGF: A prospective pilot study","volume":"2018","author":"Giancipoli E","year":"2018","unstructured":"Giancipoli E, , Pinna A, , Boscia F, et al. Intravitreal dexamethasone in patients with wet age-related macular degeneration resistant to anti-VEGF: A prospective pilot study. J Ophthalmol, 2018; 2018:5612342 doi: 10.1155\/2018\/5612342","journal-title":"J Ophthalmol"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2014-305684"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.3928\/23258160-20170329-07"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2017.03.002"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2015.09.002"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S138922"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S79948"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-022-02248-5"}],"container-title":["Journal of Ocular Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/jop.2023.0105","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jop.2023.0105","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jop.2023.0105","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T14:45:59Z","timestamp":1777646759000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/jop.2023.0105"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,1]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,8,1]]}},"alternative-id":["10.1089\/jop.2023.0105"],"URL":"https:\/\/doi.org\/10.1089\/jop.2023.0105","relation":{},"ISSN":["1080-7683","1557-7732"],"issn-type":[{"value":"1080-7683","type":"print"},{"value":"1557-7732","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,1]]}}}